Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 6, 2010, Pages 1840-1843

  Kakuta, Hiroki ^a   Fukai, Ryosuke ^a   Xiaoxia, Zheng ^a   Ohsawa, Fuminori ^a   Bamba, Takeshi ^b   Hirata, Kazumasa ^b   Tai, Akihiro ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c PREFECTURAL UNIVERSITY OF HIROSHIMA   (Japan)

Author keywords

COX 1 inhibitor; LC MS MS; Metabolite; Molecular design; UV vis

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; DIAMINOPYRIDINE; DRUG METABOLITE; N (5 AMINO 2 PYRIDINYL) 4 TRIFLUOROMETHYLBENZAMIDE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ARTICLE; DRUG IDENTIFICATION; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MEDICAL RESEARCH; METABOLITE; STOMACH INJURY; ULTRAVIOLET RADIATION; URINALYSIS; URINE COLOR;

AMINOPYRIDINES; BENZAMIDES; CHROMATOGRAPHY, LIQUID; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY;

EID: 77549086418     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.161     Document Type: Article

References (17)

1. For example:. Abdel-Tawab M., Zettl H., and Schubert-Zsilavecz M. Curr. Med. Chem. 16 (2009) 2042
2. Herschman H.R. Biochem. Biophys. Acta 1299 (1996) 125
3. Fu J.Y., Masferrer J.L., Seibert K., and Raz A. J. Biol. Chem. 265 (1990) 16737
4. Chandrasekharan N.V., Dai H., Roos K.L., Evanson N.K., Tomsik J., Elton T.S., and Simmons D.L. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13926
5. Davies N.M., and Wallace J.L. J. Gastroenterol. 32 (1997) 127
6. Richy F., Bruyere O., Ethgen O., Rabenda V., Bouvenot G., Audran M., Herrero-Beaumont G., Moore A., Eliakim R., Haim M., and Reginster J.Y. Ann. Rheum. Dis. 766 (2004) 759
7. Mukherjee D., Nissen S.E., and Topol E.J. JAMA 286 (2001) 954
8. Allison M.C., Howatson A.G., Torrance C.J., Lee F.D., and Russell R.I. N. Eng. J. Med. 327 (1992) 749
9. Vane J.R., Bakhle Y.S., and Botting R.M. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97
10. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7563
11. Wallace J.L., McKnight W., Reuter B.K., and Vergnolle N. Gastroenterology 119 (2000) 706
12. Goto K., Ochi H., Yasunaga Y., Matsuyuki H., Imayoshi T., Kusuhara H., and Okumoto T. Prostaglandins Other Lipid Mediat. 56 (1998) 245
13. Zheng X., Oda H., Takamatsu K., Sugimoto Y., Tai A., Akaho E., Ali H.I., Oshiki T., Kakuta H., and Sasaki K. Bioorg. Med. Chem. 15 (2007) 1014 Erratum in Bioorg. Med. Chem. 2007, 15, 3299
14. Zheng X., Oda H., Harada S., Sugimoto Y., Tai A., Sasaki K., and Kakuta H. J. Pharm. Sci. 97 (2008) 5446
15. Kakuta H., Zheng X., Oda H., Harada S., Sugimoto Y., Sasaki K., and Tai A. J. Med. Chem. 51 (2008) 2400
16. Urine samples were gathered from rats 4 h later after the administration of TFAP (300 mg/kg) (n = 3), and diluted in 1000-times with 5 mM sodium formate/formic acid buffer (pH 5.0) in MeOH (40/60 V/V).
17. Mortensen R.W., Corcoran O., Cornett C., Sidelmann U.G., Troke J., Lindon J.C., Nicholson J.K., and Hansen S.H. J. Pharm. Biomed. Anal. 24 (2001) 477